Regeneron Pharmaceuticals (NQ:REGN)

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Topics Stocks

FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder ↗

September 26, 2025

The U.S.

Via Benzinga

September 26, 2025

Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.1% in the afternoon session after the company highlighted challenges, including regulatory approvals and competitive pressures, at a healthcare...

Why Regeneron (REGN) Shares Are Falling Today

September 25, 2025

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗

September 25, 2025

Via Benzinga

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

September 25, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its...

What Does the Market Think About Regeneron Pharmaceuticals? ↗

September 24, 2025

Via Benzinga

Why Regeneron (REGN) Stock Is Down Today

September 23, 2025

Wall Street paused on Tuesday after three straight sessions of strong gains that pushed major large-cap indices to fresh records.

Wall Street Pauses For A Breather, Small Caps Soar: What's Moving Markets Tuesday? ↗

September 23, 2025

Via Benzinga

Discover which S&P500 stocks are making waves on Tuesday. ↗

September 23, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗

September 23, 2025

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market.

Via Benzinga

Tuesday's session: gap up and gap down stock in the S&P500 index ↗

September 23, 2025

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends.

Via Chartmill

1 S&P 500 Stock on Our Buy List and 2 We Turn Down

September 23, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025.

Topics Stocks

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision ↗

September 22, 2025

Via Benzinga

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

September 22, 2025

REGENERON PHARMACEUTICALS (NASDAQ:REGN) Screens as a Top Value Stock with Strong Fundamentals ↗

September 20, 2025

Regeneron Pharmaceuticals (REGN) is a top value stock with a low P/E ratio, strong profitability, and excellent financial health, offering a potential margin of safety for investors.

Via Chartmill

Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J? ↗

September 19, 2025

The company is looking to take on Johnson & Johnson in treating patients with a precursor to multiple myeloma.

Via Investor's Business Daily

Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks

September 19, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

1 Cash-Heavy Stock to Research Further and 2 We Brush Off

September 19, 2025

Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder ↗

September 17, 2025

Regeneron's Phase 3 trial of garetosmab showed a 90%+ reduction in new bone lesions for FOP, with no deaths and good safety over 56 weeks.

Via Benzinga

Topics Death

Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD

September 17, 2025

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

September 17, 2025

U.S. Economy Braces for Significant Slowdown: Leading Indicators Signal Weakening, Not Yet Recession

September 15, 2025

The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Tariffs Cast a Long Shadow: Consumer Prices Soar Across Essential Goods

September 10, 2025

American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products,...

Via MarketMinute

Topics Economy Government World Trade

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

September 09, 2025

From Bragar Eagel & Squire

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy ↗

September 09, 2025

Libtayo plus chemotherapy showed superior survival and response rates over five years in advanced NSCLC patients without EGFR, ALK, or ROS1 mutations.

Via Benzinga

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

September 09, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

3 Cash-Producing Stocks That Concern Us

September 09, 2025